| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
11,673 |
9,629 |
$7.12M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
61,049 |
45,579 |
$5.15M |
| G0378 |
Hospital observation service, per hour |
4,935 |
3,856 |
$5.09M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
56,490 |
41,896 |
$4.73M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
117,616 |
89,766 |
$4.33M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
14,302 |
12,147 |
$4.13M |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
41,510 |
31,270 |
$3.25M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
4,846 |
4,233 |
$3.15M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
58,286 |
44,941 |
$2.58M |
| 80053 |
Comprehensive metabolic panel |
68,890 |
54,575 |
$2.52M |
| 80061 |
Lipid panel |
74,520 |
62,264 |
$2.36M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
24,184 |
19,600 |
$2.32M |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
35,964 |
30,128 |
$2.17M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,389 |
10,237 |
$1.99M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
14,619 |
9,088 |
$1.89M |
| 84443 |
Thyroid stimulating hormone (TSH) |
53,203 |
43,567 |
$1.88M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,749 |
7,468 |
$1.78M |
| 87481 |
|
8,306 |
5,239 |
$1.65M |
| 82248 |
|
26,137 |
20,260 |
$1.58M |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,452 |
4,156 |
$1.52M |
| 84484 |
|
11,374 |
7,931 |
$1.50M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
3,190 |
2,720 |
$1.49M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
5,950 |
4,408 |
$1.42M |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
7,575 |
5,949 |
$1.36M |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
23,488 |
16,245 |
$1.35M |
| 82948 |
|
6,253 |
3,365 |
$1.31M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
27,299 |
21,366 |
$1.26M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
6,121 |
4,443 |
$1.24M |
| 81514 |
|
3,216 |
3,084 |
$1.23M |
| 83036 |
Hemoglobin; glycosylated (A1C) |
51,702 |
43,654 |
$1.23M |
| 80050 |
General health panel |
22,247 |
18,650 |
$1.17M |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,394 |
3,574 |
$1.12M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
7,168 |
5,836 |
$1.12M |
| 83690 |
|
11,703 |
9,617 |
$1.12M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
4,597 |
3,681 |
$1.10M |
| 85027 |
|
41,235 |
33,142 |
$1.09M |
| 71046 |
Radiologic examination, chest; 2 views |
8,935 |
7,488 |
$1.08M |
| 81001 |
|
36,803 |
29,375 |
$1.07M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,955 |
3,092 |
$1.01M |
| 83735 |
|
18,617 |
13,234 |
$997K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
8,133 |
5,277 |
$989K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
45,750 |
36,134 |
$931K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,538 |
1,690 |
$896K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,296 |
2,618 |
$872K |
| 87536 |
|
5,265 |
4,049 |
$872K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,386 |
5,679 |
$841K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,974 |
2,153 |
$800K |
| 36415 |
Collection of venous blood by venipuncture |
92,378 |
70,933 |
$794K |
| 85610 |
|
34,942 |
16,249 |
$778K |
| 86803 |
|
21,873 |
17,611 |
$756K |
| 86780 |
|
24,333 |
18,663 |
$751K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
2,663 |
1,291 |
$742K |
| 83013 |
|
5,089 |
4,071 |
$731K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,994 |
2,089 |
$730K |
| 82728 |
|
23,961 |
20,528 |
$730K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,123 |
1,026 |
$719K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
14,591 |
4,949 |
$709K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
3,878 |
3,101 |
$662K |
| J2704 |
Injection, propofol, 10 mg |
2,502 |
1,723 |
$651K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,930 |
1,929 |
$641K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
9,414 |
6,516 |
$620K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
2,799 |
2,506 |
$619K |
| J3490 |
Unclassified drugs |
2,105 |
1,204 |
$616K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,668 |
1,054 |
$601K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
12,372 |
8,832 |
$571K |
| 81003 |
|
20,473 |
16,858 |
$569K |
| 82607 |
|
16,150 |
13,751 |
$558K |
| 84100 |
|
9,976 |
7,253 |
$537K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,806 |
2,354 |
$512K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
11,024 |
3,722 |
$510K |
| 96376 |
|
2,594 |
1,481 |
$490K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,429 |
3,547 |
$486K |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,598 |
770 |
$485K |
| 84703 |
|
5,165 |
4,121 |
$481K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
2,878 |
2,212 |
$475K |
| 87088 |
|
18,261 |
15,279 |
$472K |
| 87340 |
|
16,076 |
12,683 |
$461K |
| 93017 |
|
3,191 |
2,799 |
$440K |
| 84403 |
|
7,920 |
6,433 |
$438K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
5,929 |
2,394 |
$437K |
| 86481 |
|
5,254 |
4,849 |
$429K |
| 86140 |
|
18,005 |
13,961 |
$419K |
| 85651 |
|
21,362 |
16,682 |
$399K |
| 83605 |
|
2,611 |
1,943 |
$380K |
| 87522 |
Neg quan hep c or qual rna |
4,247 |
3,266 |
$379K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,478 |
984 |
$374K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
1,232 |
973 |
$367K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,522 |
1,910 |
$367K |
| 86003 |
|
2,262 |
1,757 |
$350K |
| 85730 |
|
4,651 |
3,652 |
$350K |
| 84439 |
|
15,527 |
12,803 |
$344K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,931 |
3,138 |
$334K |
| 84153 |
|
8,153 |
6,992 |
$327K |
| 87186 |
|
12,261 |
9,905 |
$327K |
| 86900 |
|
4,457 |
3,651 |
$325K |
| 83880 |
|
4,065 |
3,368 |
$323K |
| 86850 |
|
4,309 |
3,513 |
$321K |
| 86706 |
|
10,746 |
8,355 |
$316K |
| 87507 |
|
500 |
330 |
$315K |
| 86901 |
|
4,455 |
3,649 |
$312K |
| 86618 |
|
7,041 |
5,917 |
$305K |
| 83540 |
|
17,667 |
15,065 |
$286K |
| 84460 |
|
20,213 |
16,447 |
$270K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
823 |
552 |
$267K |
| 86360 |
|
2,936 |
2,326 |
$258K |
| 84450 |
|
19,427 |
15,661 |
$257K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,742 |
1,469 |
$255K |
| 85379 |
|
2,983 |
2,496 |
$247K |
| 80076 |
|
15,410 |
12,083 |
$246K |
| 83550 |
|
11,483 |
9,875 |
$241K |
| 87529 |
|
1,990 |
1,164 |
$241K |
| 85007 |
|
6,611 |
4,902 |
$234K |
| 83970 |
|
3,466 |
2,976 |
$233K |
| 87077 |
|
10,253 |
8,033 |
$232K |
| 82565 |
|
18,923 |
14,942 |
$227K |
| 83655 |
|
17,067 |
13,321 |
$224K |
| 71045 |
Radiologic examination, chest; single view |
1,425 |
1,116 |
$223K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
1,001 |
513 |
$218K |
| 86704 |
|
6,270 |
4,814 |
$212K |
| 82805 |
|
1,527 |
1,161 |
$212K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,015 |
775 |
$203K |
| 82670 |
|
3,310 |
2,630 |
$202K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,620 |
2,869 |
$202K |
| 86038 |
|
7,093 |
5,520 |
$197K |
| 87510 |
|
4,692 |
2,957 |
$196K |
| 87480 |
|
4,688 |
2,952 |
$196K |
| 97161 |
|
1,809 |
1,513 |
$193K |
| 86762 |
|
5,097 |
4,087 |
$193K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
3,298 |
3,160 |
$192K |
| 84702 |
|
4,527 |
3,115 |
$188K |
| 93797 |
|
2,359 |
481 |
$187K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
881 |
611 |
$185K |
| 87070 |
|
6,881 |
5,789 |
$185K |
| 80074 |
|
1,944 |
1,459 |
$182K |
| 82550 |
|
6,203 |
5,130 |
$181K |
| 93350 |
|
742 |
629 |
$178K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,264 |
1,056 |
$177K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
759 |
595 |
$175K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,199 |
2,144 |
$172K |
| 86787 |
|
4,970 |
3,958 |
$170K |
| 86359 |
|
2,922 |
2,314 |
$166K |
| 81025 |
|
2,403 |
1,916 |
$166K |
| 82746 |
|
6,055 |
5,163 |
$166K |
| 84270 |
|
3,685 |
2,814 |
$165K |
| 82043 |
|
12,751 |
10,845 |
$163K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
758 |
723 |
$163K |
| 83001 |
|
3,828 |
3,183 |
$161K |
| 87660 |
|
4,678 |
2,949 |
$159K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
891 |
687 |
$158K |
| 88304 |
|
734 |
498 |
$154K |
| 86235 |
|
2,086 |
1,677 |
$147K |
| 84146 |
|
3,394 |
2,731 |
$145K |
| C1769 |
Guide wire |
494 |
315 |
$141K |
| 87081 |
|
1,257 |
832 |
$138K |
| 82652 |
|
1,674 |
1,443 |
$136K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
934 |
676 |
$130K |
| 83516 |
|
3,810 |
2,657 |
$129K |
| 84520 |
|
12,163 |
9,450 |
$125K |
| 86617 |
|
1,745 |
1,236 |
$124K |
| 82784 |
|
4,646 |
3,715 |
$123K |
| 87205 |
|
5,161 |
4,254 |
$123K |
| 97803 |
|
2,271 |
1,859 |
$122K |
| 83002 |
|
2,898 |
2,386 |
$121K |
| 97162 |
|
1,100 |
929 |
$121K |
| 86665 |
|
1,448 |
1,022 |
$121K |
| J2060 |
Injection, lorazepam, 2 mg |
875 |
611 |
$118K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
377 |
299 |
$117K |
| 84480 |
|
3,424 |
2,777 |
$115K |
| 93798 |
|
1,450 |
356 |
$114K |
| 80051 |
|
8,422 |
6,252 |
$113K |
| 87505 |
|
544 |
371 |
$110K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
501 |
390 |
$109K |
| 97804 |
|
1,090 |
645 |
$105K |
| 86160 |
|
2,069 |
1,742 |
$104K |
| 73560 |
|
805 |
650 |
$104K |
| 86708 |
|
2,771 |
1,948 |
$100K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
1,518 |
680 |
$98K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,317 |
615 |
$97K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
596 |
412 |
$96K |
| 87040 |
|
745 |
421 |
$96K |
| 87902 |
|
263 |
208 |
$95K |
| 83721 |
|
4,106 |
3,243 |
$94K |
| 84550 |
|
5,309 |
4,392 |
$94K |
| 87147 |
|
2,165 |
1,199 |
$92K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
371 |
278 |
$91K |
| 71250 |
|
396 |
319 |
$91K |
| 85014 |
|
4,707 |
3,726 |
$90K |
| 85018 |
|
4,726 |
3,732 |
$90K |
| 83020 |
|
2,370 |
1,796 |
$88K |
| 93975 |
|
332 |
269 |
$82K |
| 82570 |
|
5,369 |
3,785 |
$81K |
| 82947 |
|
7,914 |
6,271 |
$81K |
| 86735 |
|
2,557 |
2,005 |
$78K |
| 86765 |
|
2,611 |
2,046 |
$78K |
| J1815 |
Injection, insulin, per 5 units |
148 |
70 |
$77K |
| 99153 |
Mod sedat endo service >5yrs |
397 |
318 |
$76K |
| G0328 |
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous |
2,628 |
2,164 |
$75K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
415 |
351 |
$75K |
| 86696 |
|
1,401 |
845 |
$74K |
| 84425 |
|
3,280 |
2,763 |
$73K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
401 |
356 |
$73K |
| 82310 |
|
4,312 |
3,296 |
$72K |
| 86039 |
|
2,822 |
2,216 |
$71K |
| 86431 |
|
4,660 |
3,743 |
$71K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
370 |
253 |
$70K |
| 84134 |
|
2,140 |
1,561 |
$70K |
| 96367 |
|
128 |
99 |
$68K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
338 |
243 |
$67K |
| 82040 |
|
6,138 |
4,612 |
$67K |
| 87650 |
|
1,687 |
1,639 |
$66K |
| 80164 |
|
1,962 |
1,413 |
$66K |
| 86480 |
|
1,172 |
661 |
$65K |
| 86225 |
|
2,035 |
1,726 |
$64K |
| 99152 |
|
341 |
267 |
$64K |
| 84481 |
|
3,306 |
2,813 |
$63K |
| 88342 |
|
392 |
268 |
$63K |
| 93971 |
|
805 |
624 |
$61K |
| 86200 |
|
2,374 |
1,918 |
$61K |
| 86695 |
|
1,248 |
745 |
$59K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
447 |
388 |
$56K |
| 86592 |
|
2,892 |
2,302 |
$56K |
| 87641 |
|
1,154 |
931 |
$56K |
| 87640 |
|
1,144 |
943 |
$56K |
| 82140 |
|
1,242 |
914 |
$54K |
| 83615 |
|
2,719 |
2,084 |
$54K |
| 93296 |
|
741 |
726 |
$54K |
| 86664 |
|
1,398 |
1,018 |
$54K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
337 |
233 |
$53K |
| 84466 |
|
1,818 |
1,595 |
$52K |
| S9433 |
Medical food nutritionally complete, administered orally, providing 100% of nutritional intake |
863 |
200 |
$52K |
| 70498 |
|
179 |
140 |
$51K |
| 82105 |
|
1,339 |
1,131 |
$49K |
| 70496 |
|
164 |
129 |
$48K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
93 |
73 |
$48K |
| 86663 |
|
1,398 |
1,018 |
$47K |
| 82627 |
|
950 |
765 |
$47K |
| 82150 |
|
2,819 |
2,289 |
$47K |
| 86376 |
|
1,340 |
1,090 |
$47K |
| 83993 |
|
1,247 |
1,049 |
$45K |
| 86364 |
|
2,198 |
2,115 |
$44K |
| 82465 |
|
3,865 |
2,932 |
$44K |
| 77080 |
|
475 |
353 |
$43K |
| 73630 |
|
358 |
288 |
$43K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
102 |
84 |
$43K |
| 84156 |
|
4,055 |
3,343 |
$42K |
| 82533 |
|
1,024 |
840 |
$42K |
| 87653 |
|
615 |
414 |
$40K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
20 |
12 |
$40K |
| 88141 |
|
1,431 |
642 |
$39K |
| 97535 |
Self-care/home management training, each 15 minutes |
1,001 |
667 |
$39K |
| 84207 |
|
619 |
560 |
$38K |
| 85060 |
|
1,658 |
1,142 |
$38K |
| 84402 |
|
646 |
558 |
$38K |
| 83718 |
|
2,050 |
1,482 |
$37K |
| 84075 |
|
2,463 |
1,760 |
$36K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
545 |
307 |
$36K |
| 80197 |
|
2,480 |
1,435 |
$36K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
609 |
325 |
$35K |
| 83525 |
|
1,311 |
977 |
$34K |
| 86308 |
|
1,243 |
911 |
$33K |
| J2785 |
Injection, regadenoson, 0.1 mg |
153 |
113 |
$32K |
| 82950 |
|
2,609 |
2,129 |
$31K |
| 93225 |
|
356 |
315 |
$31K |
| 86800 |
|
861 |
657 |
$31K |
| 73030 |
|
409 |
311 |
$30K |
| 82977 |
|
1,829 |
1,453 |
$30K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
75 |
65 |
$30K |
| 84436 |
|
1,916 |
1,407 |
$29K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
194 |
163 |
$29K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
249 |
184 |
$29K |
| 88112 |
|
245 |
219 |
$29K |
| 85045 |
|
2,026 |
1,558 |
$27K |
| 82247 |
|
2,208 |
1,405 |
$27K |
| 84132 |
|
2,361 |
1,870 |
$26K |
| 73130 |
|
243 |
183 |
$26K |
| 86705 |
|
805 |
584 |
$26K |
| 87015 |
|
494 |
440 |
$26K |
| 73610 |
|
189 |
149 |
$25K |
| 82785 |
|
519 |
508 |
$25K |
| 76813 |
|
194 |
113 |
$24K |
| 87517 |
|
278 |
202 |
$23K |
| 84155 |
|
1,709 |
1,260 |
$23K |
| 80069 |
|
2,048 |
1,410 |
$23K |
| 88341 |
|
106 |
61 |
$22K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
13 |
12 |
$22K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
62 |
45 |
$22K |
| 80178 |
|
1,322 |
995 |
$22K |
| 97166 |
|
119 |
94 |
$21K |
| 87338 |
|
825 |
674 |
$21K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
45 |
38 |
$21K |
| 84165 |
|
915 |
764 |
$21K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
474 |
468 |
$20K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,375 |
3,889 |
$19K |
| 86666 |
|
335 |
260 |
$19K |
| 84478 |
|
1,184 |
798 |
$19K |
| 84295 |
|
799 |
593 |
$18K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
270 |
231 |
$18K |
| 83520 |
|
550 |
315 |
$17K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
121 |
119 |
$17K |
| 86147 |
|
126 |
100 |
$16K |
| 86753 |
|
353 |
285 |
$16K |
| 97802 |
|
134 |
118 |
$16K |
| 93299 |
|
261 |
206 |
$15K |
| 72100 |
|
124 |
114 |
$14K |
| 86593 |
|
569 |
492 |
$14K |
| G0424 |
Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day |
399 |
40 |
$14K |
| 76830 |
Ultrasound, transvaginal |
83 |
55 |
$14K |
| 86256 |
|
538 |
242 |
$13K |
| 83498 |
|
219 |
173 |
$13K |
| 87901 |
|
33 |
13 |
$13K |
| 82747 |
|
298 |
283 |
$13K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
298 |
283 |
$12K |
| 99412 |
|
340 |
120 |
$12K |
| 93246 |
|
238 |
232 |
$12K |
| 73502 |
|
214 |
167 |
$11K |
| 84300 |
|
304 |
192 |
$10K |
| 87184 |
|
352 |
275 |
$10K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
63 |
62 |
$10K |
| 87493 |
|
166 |
112 |
$9K |
| 84590 |
|
298 |
283 |
$9K |
| 94060 |
|
72 |
64 |
$8K |
| 97165 |
|
38 |
26 |
$8K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
86 |
51 |
$8K |
| 87799 |
|
148 |
112 |
$8K |
| 73590 |
|
50 |
41 |
$8K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
26 |
25 |
$8K |
| 86709 |
|
262 |
180 |
$8K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
21 |
12 |
$8K |
| J1071 |
Injection, testosterone cypionate, 1 mg |
1,244 |
529 |
$7K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
39 |
39 |
$7K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
70 |
51 |
$7K |
| 83921 |
|
257 |
198 |
$7K |
| 86141 |
|
303 |
201 |
$7K |
| G0008 |
Administration of influenza virus vaccine |
191 |
167 |
$7K |
| 84305 |
|
153 |
137 |
$6K |
| 86258 |
|
148 |
131 |
$6K |
| 87207 |
|
246 |
238 |
$6K |
| 86146 |
|
62 |
43 |
$6K |
| ATP08 |
|
1,991 |
1,346 |
$6K |
| 87625 |
|
89 |
40 |
$6K |
| 84252 |
|
110 |
110 |
$6K |
| 93298 |
|
69 |
68 |
$6K |
| 82274 |
|
223 |
216 |
$6K |
| 93325 |
|
28 |
25 |
$5K |
| 84630 |
|
168 |
156 |
$5K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
44 |
29 |
$5K |
| 99215 |
Prolong outpt/office vis |
26 |
26 |
$5K |
| 82951 |
|
151 |
107 |
$4K |
| 82330 |
|
197 |
186 |
$4K |
| 86677 |
|
144 |
44 |
$4K |
| 94729 |
|
64 |
53 |
$4K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
27 |
14 |
$4K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
86 |
64 |
$4K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
81 |
60 |
$4K |
| 83090 |
|
128 |
107 |
$4K |
| 94727 |
|
55 |
42 |
$4K |
| 87140 |
|
232 |
230 |
$3K |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
49 |
43 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
162 |
127 |
$3K |
| 74246 |
|
32 |
15 |
$3K |
| 86255 |
|
124 |
48 |
$3K |
| 0002A |
|
95 |
94 |
$3K |
| 82525 |
|
98 |
94 |
$3K |
| J1630 |
Injection, haloperidol, up to 5 mg |
17 |
13 |
$3K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
34 |
26 |
$3K |
| 90715 |
|
29 |
26 |
$3K |
| C9113 |
Injection, pantoprazole sodium, per vial |
24 |
14 |
$3K |
| 0001A |
|
109 |
105 |
$2K |
| 86231 |
|
104 |
99 |
$2K |
| 84154 |
|
22 |
14 |
$2K |
| 93280 |
|
173 |
140 |
$2K |
| 93320 |
|
12 |
12 |
$2K |
| 80177 |
|
67 |
39 |
$2K |
| 72170 |
|
16 |
12 |
$2K |
| 82374 |
|
15 |
12 |
$2K |
| 73110 |
|
34 |
28 |
$2K |
| 93270 |
|
14 |
14 |
$1K |
| 87430 |
|
62 |
46 |
$1K |
| 82952 |
|
151 |
107 |
$1K |
| 83519 |
|
43 |
29 |
$1K |
| 90662 |
|
55 |
46 |
$1K |
| 86694 |
|
38 |
37 |
$1K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
14 |
12 |
$1K |
| G0239 |
Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) |
65 |
12 |
$1K |
| 86334 |
|
41 |
39 |
$1K |
| 82010 |
|
22 |
12 |
$1K |
| G1011 |
Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program |
21 |
15 |
$950.68 |
| 93880 |
|
13 |
13 |
$846.54 |
| 85612 |
|
26 |
25 |
$809.73 |
| 85613 |
|
26 |
25 |
$803.14 |
| 86769 |
|
12 |
12 |
$796.65 |
| 86355 |
|
14 |
13 |
$726.67 |
| 86357 |
|
14 |
13 |
$725.47 |
| 93290 |
|
17 |
12 |
$723.03 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
29 |
28 |
$711.64 |
| 99201 |
|
12 |
12 |
$660.36 |
| 0012A |
|
17 |
17 |
$590.75 |
| 87206 |
|
62 |
43 |
$588.77 |
| 82340 |
|
39 |
39 |
$576.88 |
| 84133 |
|
28 |
26 |
$570.82 |
| 80305 |
|
30 |
12 |
$549.92 |
| 86328 |
|
12 |
12 |
$501.21 |
| 82435 |
|
40 |
37 |
$486.49 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
67 |
65 |
$472.88 |
| ATP15 |
|
55 |
52 |
$447.54 |
| 86381 |
|
13 |
13 |
$444.05 |
| 87075 |
|
21 |
12 |
$429.22 |
| 85240 |
|
12 |
12 |
$427.36 |
| 82103 |
|
13 |
12 |
$426.22 |
| 74018 |
|
15 |
13 |
$409.70 |
| 82397 |
|
13 |
13 |
$397.75 |
| 83695 |
|
12 |
12 |
$347.35 |
| 0011A |
|
17 |
17 |
$341.36 |
| 82390 |
|
13 |
13 |
$339.55 |
| 82180 |
|
13 |
13 |
$306.78 |
| 86036 |
|
16 |
16 |
$299.78 |
| 93282 |
|
12 |
12 |
$296.39 |
| 87102 |
|
18 |
13 |
$172.20 |
| 82436 |
|
14 |
12 |
$140.61 |
| ATP14 |
|
78 |
50 |
$120.93 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
139 |
139 |
$37.28 |
| ATP10 |
|
27 |
14 |
$17.92 |
| 0250 |
|
1,844 |
659 |
$0.00 |